RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript
Source: SeekingAlpha
2025-10-20 17:05:38 ET
RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria October 20, 2025 8:30 AM EDT...
Read the full article on Seeking Alpha
For further details see:
RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript
RAPT Therapeutics Inc.
NASDAQ: RAPT
RAPT Trading
0.07% G/L:
$57.995 Last:
8,357,151 Volume:
$57.98 Open:
RAPT Latest News
February 25, 2026 03:19:51 pm
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
February 11, 2026 08:02:00 pm
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
February 06, 2026 04:29:00 pm
Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders
January 28, 2026 06:41:00 pm
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
RAPT Stock Data
$1,601,411,235
19,597,128
0.05%
18
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
